RNAZ Transcode Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1829635 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-435.7%
TTM EPS YoY81.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-866.1%
ROA-581.7%
ROIC (approx.)-909.8%
Asset turnover—
Leverage & solvency
Liabilities / assets28.2%
Debt / equity0.00x
Current ratio0.96x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.18x
Accruals ratio-476.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $3.55M | $3.69M | $5.11M | $5.48M | $3.16M | $2.57M | $2.22M | $3.64M |
| SG&A expense | $3.76M | $2.54M | $2.22M | $1.76M | $1.40M | $1.66M | $951,652 | $1.45M |
| Operating income | -$109.69M | -$6.79M | -$17.76M | -$16.03M | -$4.56M | -$4.22M | -$3.17M | -$5.09M |
| Interest expense | $6,979 | — | — | $542 | $5,960 | $0 | $114 | $1,832 |
| Pretax income | -$107.70M | -$6.75M | -$17.55M | -$13.22M | -$4.86M | -$4.28M | -$12.09M | — |
| Income tax | — | — | — | $226,069 | $0 | $0 | $0 | $0 |
| Net income | -$107.38M | -$6.75M | -$17.79M | -$13.44M | -$4.86M | -$4.28M | -$12.09M | -$5.92M |
| EBITDA | -$109.66M | -$6.77M | -$17.73M | -$15.98M | -$4.56M | -$4.21M | -$3.16M | -$5.08M |
| EPS (basic) | -9.36 | -7.17 | -21.28 | — | -5.82 | -5.13 | -70.16 | — |
| EPS (diluted) | -9.36 | -7.17 | -21.28 | — | -5.82 | -5.13 | -70.16 | — |
| Weighted avg. shares (diluted) | 11.47M | 957,191 | 916,968 | — | 833,683 | 833,653 | 172,262 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $4.64M | $8.38M | $12.84M | $17.81M | $2.84M | $7.37M | $11.57M | $5.81M |
| Current assets | $6.70M | $10.64M | $16.75M | $21.98M | $4.75M | $8.24M | $13.04M | $7.09M |
| PP&E, net | $9,326 | $322,809 | $346,745 | $370,681 | $19,908 | $24,689 | $38,131 | $51,574 |
| Goodwill | $25.74M | $25.74M | $25.74M | $25.74M | — | — | — | — |
| Intangibles | $12.30M | $114.30M | $114.30M | $114.30M | — | — | — | — |
| Total assets | $44.75M | $151.01M | $157.16M | $162.40M | $5.23M | $8.27M | $13.19M | $7.29M |
| Current liabilities | $6.98M | $5.40M | $5.38M | $3.49M | $2.97M | $1.56M | $2.51M | $2.77M |
| Total liabilities | $12.61M | $12.65M | $12.64M | $10.52M | $3.80M | $2.12M | $2.90M | $9.31M |
| Shareholders' equity | $32.14M | -$27.69M | $1.25M | $10.34M | $1.43M | $6.15M | $10.29M | -$2.02M |
| Shares outstanding | 17.24M | 1.01M | 916,968 | 916,968 | 833,683 | 833,683 | 23.34M | 36,753 |
| Cash flow statement | ||||||||
| Operating cash flow | -$7.66M | -$5.40M | -$4.98M | -$8.14M | -$4.08M | -$4.19M | -$3.10M | -$3.15M |
| Capital expenditure | — | — | — | — | — | — | — | $500 |
| Free cash flow | — | — | — | — | — | — | — | -$3.15M |
| Investing cash flow | — | — | — | — | — | — | — | -$500 |
| Financing cash flow | $3.92M | — | — | $23.12M | -$455,726 | $0 | $8.85M | $7.08M |
| Depreciation & amortization | $21,812 | $23,937 | $23,936 | $44,780 | $4,781 | $13,443 | $13,443 | $10,346 |
| Stock-based compensation | $315,314 | — | — | $61,865 | $134,324 | $131,510 | $157,729 | $168,770 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.